Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar Initial Dosing in Stage V CKD
NCT00091481Phase 4Completed
- Sponsor
- Abbott Laboratories
- Start
- Jun 2003
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of paricalcitol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Incidence rate of at least two consecutive calcium-phosphorus product levels greater than 65. Started Jun 2003; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00091481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091481.